Going Forward in Reverse: Navigating Treatment for Acute Major Bleeding

Note: If you attended the live CE activity AND received CE credit (i.e. a pharmacist CE statement of credit with ACPE UAN 0221-0000-18-387-L01-P), you are NOT allowed to also receive credit for this home-study on-demand web activity.

Activity Description

There are many types of bleeding, but bleeding secondary to anticoagulant use presents a complicated and multifactorial challenge. If the bleed is classified as major, at a critical site or life threatening, anticoagulant reversal may be considered. The decision on which reversal agent to use is highly complex, and the area of anticoagulation reversal is rapidly changing.

The goal of this educational activity is to enhance the pharmacist’s knowledge of the impact of acute major bleeding and patient assessment and management options. Content will include reviewing the most recent key takeaways from the American College of Cardiology (ACC) guideline updates, reversal treatment options, and a discussion on analyzing the appropriateness of reversal use. This will be an interactive session, to include Q&A with the faculty as well as audience-response polling and decision-making exercises.

Learning Objectives

The target audience for this session includes health-system and managed care pharmacists, including chief pharmacy officers and pharmacy directors. At the completion of this symposium, the participant will be able to:

  • Identify and assess patients with an acute major bleed in order to recommend appropriateness of anticoagulation reversal.
  • Compare and contrast current FDA approved therapies that can be employed to reverse oral anticoagulation.
  • Identify patient specific factors and criteria that impact the decision of which reversal agent to utilize and associated monitoring parameters.


Scott T. Benken, PharmD, BCPS-AQ Cardiology, FCCM
MICU/CTICU Clinical Pharmacist
University of Illinois Medical Center
Clinical Assistant Professor
University of Illinois-Chicago College of Pharmacy
Chicago, Illinois

Joe Bodkin, PharmD, BCCCP
Clinical Pharmacist - Critical Care
Department of Pharmacy
Northwestern Medicine
Chicago, Illinois

Jessica M. Rimsans, PharmD, BCPS
Clinical Pharmacy Specialist
Hemostatic and Antithrombotic Stewardship
Brigham and Women’s Hospital
Department of Pharmacy Services
Boston, Massachusetts

CE Accreditation

Release Date: 1-25-2019
Expiration Date: 1-25-2022


ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-19-052-H01-P has been assigned to this home study knowledge-based activity (initial release date 1-25-19). This activity is approved for 1.5 contact hours (0.15 CEUs) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation to receive pharmacy CE credit. Statements of completion will be issued online at www.ProCE.com and proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.


It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. Benken is a Speaker for La Jolla Pharmaceuticals. Dr. Bodkin has no relevant commercial or financial relationships to disclose. Dr. Rimsans has no relevant commercial or financial relationships to disclose. A portion of grant funds received by ProCE from Portola Pharmaceuticals, Inc. will be used to compensate the faculty for this presentation.

Please note: The opinions expressed in this activity should not be construed as those of the CE provider or Portola Pharmaceuticals, Inc. The information and views presented in this activity are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs and/or devices for unlabeled indications, which should be considered experimental. Participants are advised to consult manufacturer product information and the professional literature, and use professional judgment in applying the presented information in patient-care activities.


This activity is provided by ProCE, Inc. and is supported by an educational grant from Portola Pharmaceuticals, Inc.


The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.